Gary Giarratano joins Radient Pharmaceuticals

Takes position of director of North American sales and marketing

Radient Pharmaceuticals Corporation (RPC) has appointed Gary Giarratano as director of North American sales and marketing. He will also be responsible for managing sales of the firm’s Onko-Sure in vitro diagnostic (IVD) cancer test.

Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.

‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.

You may also like

Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Manufacturing

IMed Consultancy helps Toby Orthopaedics navigate UK regulations

Regulatory consultancy ensures compliance and confidence for Miami-based company
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Design & Build

Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies

Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
Subscribe now